Condition: Lung Cancer Patients · Non-small Cell Lung Cancer (NSCLC) · Sponsor: Marc de Perrot
The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery. Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery.
This description comes directly from the study's public registry record.
Marc de Perrot, MD, FRCSC · 4163405549 · marc.deperrot@uhn.ca
Fatemeh Zaeimi, MSc · 4163405686 · fatemeh.zaeimi@uhn.ca
Always discuss trial participation with your own doctor first.
| Toronto General Hospital | Toronto, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06331455